Literature DB >> 36029148

Haemagglutinin, neuraminidase and haemagglutinin esterase on the surface of SARS-CoV-2?

Emad Behboudi1, Hossein Teimouri1.   

Abstract

Entities:  

Year:  2022        PMID: 36029148      PMCID: PMC9539279          DOI: 10.1002/rmv.2384

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   11.043


× No keyword cloud information.
coronavirus disease 2019 human coronavirus OC43 haemagglutinin‐esterase human coronavirus HKU1 open reading frames severe acute respiratory syndrome‐coronavirus‐2 Dear Editor We read an article by Alketbi et al., in which the authors stated that ‘Binding of surfactant proteins (SP), which importantly contribute to the surfactant behaviour as a defence system, to the virus occurs by recognition of haemagglutinin and neuraminidase glycans on the surface of the virus, thereby hindering the ability of the virus to enter the cell. However, the hemagglutinins found on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) exhibit antigenic variations that resulted in reduced binding, leading to greater virulence and subsequent high mortality and morbidity in patients. SARS‐CoV‐2 haemagglutinin‐esterase (HE) provides classical glycan‐binding lectin activity, while exhibiting haemagglutination and destruction of the surfactant proteins’. However, according to the scientific evidence and phylogenetic analysis of the genome of SARS‐CoV‐2 lacks the haemagglutinin, neuraminidase, and HE gene and it has no HE glycoprotein, thus HE can't be used for the SARS‐CoV‐2 entry. Severe acute respiratory syndrome coronavirus 2, the viral agent of COVID‐19, belongs to betacoronavirus genera (lineage B) and is the third agent of coronavirus related epidemics in the last two decades after SARS‐CoV and MERS‐CoV. , According to virology text, betacoronaviruses have four structural proteins, including spike glycoprotein (S), envelope protein (E), membrane protein (M), nucleocapsid protein (N). , , Although the lineage A betacoronaviruses such as HKU1‐CoV, and HCoV‐OC43 can encode HE, the betacoronaviruses lineage B including SARS‐CoV‐2 cannot encode HE glycoprotein. ,

AUTHOR CONTRIBUTIONS

Conceptualisation, writing‐original draft, and review: Emad Behboudi; Supervision, review and editing: Hossein Teimouri.

CONFLICT OF INTEREST

No conflict of interest declared.
  6 in total

Review 1.  Lipid-based therapies against SARS-CoV-2 infection.

Authors:  Eman Humaid Alketbi; Rania Hamdy; Abdalla El-Kabalawy; Viktorija Juric; Marc Pignitter; Kareem A Mosa; Ahmed M Almehdi; Ali A El-Keblawy; Sameh S M Soliman
Journal:  Rev Med Virol       Date:  2021-01-13       Impact factor: 11.043

Review 2.  The structure and functions of coronavirus genomic 3' and 5' ends.

Authors:  Dong Yang; Julian L Leibowitz
Journal:  Virus Res       Date:  2015-02-28       Impact factor: 3.303

3.  Genotyping coronavirus SARS-CoV-2: methods and implications.

Authors:  Changchuan Yin
Journal:  Genomics       Date:  2020-04-27       Impact factor: 5.736

4.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.

Authors:  Jasper Fuk-Woo Chan; Kin-Hang Kok; Zheng Zhu; Hin Chu; Kelvin Kai-Wang To; Shuofeng Yuan; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2020-01-28       Impact factor: 7.163

5.  Role of Glycoprotein Hemagglutinin-Esterase in COVID-19 Pathophysiology?

Authors:  Milad Zandi; Emad Behboudi; Saber Soltani
Journal:  Stem Cell Rev Rep       Date:  2021-06-28       Impact factor: 5.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.